A Phase 2 interventional study of Alpelisib and Placebo in PIK3CA-related Overgrowth Spectrum (PROS), sponsored by Novartis Pharmaceuticals. Active, not recruiting at 36 sites in 12 countries. Open to participants aged 0 Days to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a prospective Phase II multi-center study with an initial 16-week, randomized, double-blind, placebo-controlled period, followed by two extension periods to assess the efficacy, safety and pharmacokinetics (PK) of alpelisib in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)
This is a Phase II multi-center study with an upfront 16-week, randomized, double-blind, placebo-controlled period, and extension periods, to assess the efficacy, safety and PK of alpelisib in pediatric and adult participants with PROS.
Study period 1 - Core Period: Double-blind treatment, with an upfront 16-week placebo-controlled period (From Randomization to the end of Week 24) - Groups 1 and 2 At study start, participants in Group 1 and Group 2 will be enrolled and randomized in a 2:1 ratio (104 participants in the active arms and 52 participants in the placebo arms) to alpelisib or matching placebo. The upfront placebo-controlled period will continue for the first 16 weeks. At the conclusion of week 16, those participants who were randomized to receive placebo will be switched to active treatment with alpelisib in a blinded fashion at the dose level received at the end of the placebo period. Those participants who were randomized to receive alpelisib, will continue their treatment at the same dose level.
During the initial 16 weeks of the Core period, study treatment will be given in a blinded fashion, starting from week 17 of the Core period in open label fashion. The randomized treatment assignment to the treatment arms will remain blinded to participants, Investigators and the study team until the time of the primary analysis, when the last participant reaches week 48 from randomization or discontinues earlier.
Study period 1 - Exploratory; Group 4, open label treatment with the alpelisib FCT formulation After the implementation of Global Protocol Amendment 01, approximately 6 participants 2 to 5 years of age will be enrolled in exploratory Group 4. These participants will receive alpelisib FCT in an open label setting.
Study period 2 - Extension 1: treatment with alpelisib (week 25 up to the end of week 48) - Groups 1 and 2 Participants (Group 1 and Group 2) will continue their treatment during this study period.
For Groups 1 and 2, dose escalation is NOT allowed during first 4 weeks of Extension 1 period (weeks 25-28).
Once a participant (Groups 1 and 2) has completed initial 24 weeks of study treatment and reached Week 29, dose escalation will be allowed (Refer to Section 6.5.1):
Study period 2 - Exploratory: Group 4, open label treatment with the alpelisib FCT formulation
For Group 4 dose escalation is allowed once participant has reached the age of 6 years old, has completed the initial 24 weeks of study treatment, and has reached week 25:
Study period 3 - Extension 2: long-term treatment with alpelisib (Week 49 up to 5 years) - Groups 1 and 2 Groups 1 and 2 participants who continue the study until Week 48 and have clinical benefit from the study treatment, will enter a long-term extension period. Dose escalation and treatment beyond progression are allowed in both Group 1 and Group 2.
Study period 3 - Exploratory: Group 4, open label treatment with the alpelisib FCT formulation Group 4 participants who continue the study until Week 48 and have clinical benefit from the study treatment, will enter a long-term extension period. Dose escalation is allowed once a participant has reached the age of 6 years old, has completed the initial 24 weeks of study treatment, and has reached Week 25.
Exploratory study part: Group 3, open label treatment with the alpelisib granules formulation Group 3 will be an exploratory group of participants who are 0 to 5 years old and will receive the alpelisib granules formulation with an age-dependent starting dose and maximum dose levels ranging from 20 mg every other day to 50 mg once daily. Group 3 will be open to enrollment only after implementation of Global Protocol Amendment 05. Dose escalation is allowed once a participant has reached the age of 6 years, has completed the initial 24 weeks of study treatment, and has reached Week 25.
Group 5 open-label treatment with the alpelisib FCT formulation:
Participants of Group 5 will be enrolled after implementation of Global Protocol Amendment 02 and immediately after enrollment of Group 2 has been completed and will receive a starting dose of 125 mg alpelisib FCT formulation once daily in an open-label setting.
Dose escalation is allowed for those who did not derive sufficient clinical benefit at the Investigator's discretion and once participant has reached at least Week 25.
Study period 4 - Extension 3: treatment with alpelisib (from Week 264 until last patient enrolled completes 5 years of treatment) All participants from all groups will be followed until the last patient enrolled completes 5 years of treatment or discontinues early, to collect additional safety of alpelisib and in order to ensure patient access to treatment in the absence of global commercial supply in pediatric and adult participants with PROS. Visits will be performed every 24 weeks and additional safety assessments every 48 weeks.
It is planned to enroll approximately 192 participants in total, 78 adults and 114 children and adolescents. A total of approximately 156 male or female participants (of age ≥ 6 years) with PROS will be randomized in a 2:1 ratio in Groups 1 and 2 (approximately 78 participants per age group). Additional exploratory groups (Group 3, Group 4 and Group 5) will include approximately a total of 36 participants (approximately 15 in Group 3, 6 in Group 4 and 15 in Group 5).
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive alpelisib (125 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
Drug: Alpelisib
During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive placebo. After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
Drug: Alpelisib · Drug: Placebo
During double-blind randomized study period (from baseline up to Week 16, pediatric participants (6 to 17 years old) will be randomized to receive alpelisib (50 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
Drug: Alpelisib
During double-blind randomized study period (from baseline up to Week 16), pediatric participants (6 to 17 years old) will be randomized to receive Placebo. After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
Drug: Alpelisib · Drug: Placebo
Pediatric participants (0 to 5 years old) will receive alpelisib granules formulation with an age-dependent starting dose (\<1 month: 20 mg every other day; 1 to \<6 months: 20 mg daily; 6 to \<2 years: 40 mg daily; 2 to \<6 years: 50 mg daily).
Drug: Alpelisib
Pediatric participants (2 to 5 years old) will receive 50 mg of alpelisib film-coated tablets (FCT) once daily in an open-label setting.
Drug: Alpelisib
Pediatric participants (6 to 17 year old) will receive 125 mg alpelisib film-coated (FCT) once daily, in an open-label setting.
Drug: Alpelisib
Adult participants (group 1) will receive 125 mg of alpelisib oral tablets once daily. Pediatric participants (Group 2: 6 to 17 years old) will receive 50 mg of alpelisib oral tablets once daily. Pediatric participants (Group 4: 2 to 5 years old) will receive 50 mg of alpelisib oral tablets once daily, Pediatric participants (Group 3: 0 to 5 years old) will receive alpelisib granules formulation with an age-dependent starting dose and maximum dose levels ranging from 20 mg every other day to 50 mg once daily. Pediatric participants (Group 5: 6 to 17 years old) will receive 125 mg of alpelisib oral tablets once daily.
Also known as: BYL719
Participants will receive matching placebo once daily up to week 16.
Proportion of Participants Randomized to Alpelisib With a Confirmed Objective Response by BIRC in Group 1 and Group 2
A responder is defined by achieving a \>=20% reduction from baseline in the sum of target lesion volumes (via BIRC), provided that none of the individual target lesions have a \>=20% increase from baseline and in absence of progression of non target lesions and without new lesions. Confirmation of response requires a subsequent imaging assessment performed at least 4 weeks after the onset of response. Participants who permanently discontinued alpelisib prior to confirmation of response, and participants who received surgery as rescue therapy prior to confirmation of response are considered as non-responders.
Time frame: Up to 48 weeks
Key Secondary Objective: Proportion of Participants With Response at Week 16 by BIRC in Group 1 and Group 2
A responder is defined by achieving a \>=20% reduction from baseline in the sum of target lesion volumes (via BIRC) at Week 16, provided that none of the individual target lesions have a \>=20% increase from baseline and in absence of progression of non-target lesions and without new lesions. Participants who permanently discontinued alpelisib prior to Week 16, participants who received surgery as rescue therapy prior to Week 16, and participants who had a missing/non-evaluable radiological assessment at Week 16 are considered as non-responders.
Time frame: Week 16
Proportion of Participants With a Response at Week 24 (by BIRC) in Groups 1 and 2
A responder is defined by achieving a \>=20% reduction from baseline in the sum of target lesion volumes (via BIRC) at Week 24, provided that none of the individual target lesions have a \>=20% increase from baseline and in absence of progression of non-target lesions and without new lesions.
Time frame: Week 24
Frequency and Severity of Adverse Events in Groups 1 and 2 up to Week 16
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a participant or clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. This includes events reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative). Treatment emergent Adverse Event (TEAEs) in this study are events that started after the first dose of study treatment and until 30 days after the last dose of study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 30 days after the last study treatment.
Time frame: Up to Week 16
Frequency and Severity of Adverse Events in All Groups of Participants Over Time
Type, frequency, seriousness, and severity of treatment-emergent adverse events per CTCAE v4.03 criteria in participants with PROS over time.
Time frame: Up to approximately 5 years
Change From Baseline to Week 16 in Brief Pain Inventory (BPI) Worst Pain Intensity in Group 1 and 2
For adult and pediatric patients 12 years of age and older, the BPI item that assesses worst pain intensity in the past 24 hours was used. Patients respond to the item on an 11-point response scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). Worst pain intensity was averaged weekly over a 7-day period if a patient had completed the questionnaire for at least 4 days in the 7-day period. The weekly mean was calculated based on the available assessments. Clinically important change at Week 16 was defined as a 2-point reduction for patients who had a pain intensity score ≥ 4 at baseline. For patients with a baseline score \< 4, a 1-point reduction from baseline was also considered as a clinically important change.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 16
Number of Participants With Global Impression of Symptom Severity (PGIS) Score up to Week 16
A Patient Global Impression of Symptom Severity item was used to understand the overall severity of symptoms experienced and clinical meaningfulness of treatment effects experienced during this study. This item included 5 response options: no symptoms, mild, moderate, severe, and very severe.
Time frame: Week 4, Week 8, Week 16
Percentage Change From Baseline in Target and MRI-measurable Non- Target Lesion Volume in Group 1 and Group 2
Percentage change from baseline in the sum of target lesion volume, MRI-measurable non-target lesion volume and all MRI measurable (target an non-target) lesion volume as assessed by BIRC. Target lesions are defined as anatomically reproducibly defined tissue(s) masses, which may be composed of one or several tissue types, and can be accurately measured by imaging technique MRI. Target lesion(s) (up to 3) should be identified at screening, be at least 2 cm in the longest diameter at baseline (for each selected lesion) and may be further reproducibly assessed by MRI. MRI-measurable non-target lesions are defined as all anatomic lesions other than selected as target and may be measured at radiologic assessment (at least 2 cm in the longest diameter at baseline, the volume may be further reproducibly assessed by MRI).
Time frame: From Baseline up to approximately 5 years
Proportion of Participants With Changes From Baseline in Other Non-target Lesions in Group 1 and Group 2
Percentage change from baseline in other non-target lesions (by BIRC). Non Target lesions are defined as: * Anatomic lesions, limb/trunkal areas affected by PROS, organomegaly when they may be measured only by caliper/ruler (e.g., circumference of changed limb or body part) * Truly non-measurable lesions (e.g., small lesions less than 2 cm on MRI, superficial visual lesions, masses, organomegaly, PROS-related enlargement of anatomic area identified by physical exam that is not measurable by reproducible imaging technique)
Time frame: From Baseline up to approximately 5 years
Proportion of Participants With New Lesions in Group 1 and Group 2
The proportion of patients with new lesions (as assessed by BIRC) will be assessed throughout the study.
Time frame: From Baseline up to approximately 5 years
Pharmacokinetics (PK) of Alpelisib in Group 1 and Group 2: Maximum Concentration (Cmax)
Maximum concentration of alpelisib following drug administration will be assessed for Group 1 and Group 2. After Week 28, blood samples will be collected only for participants who had dose escalation at next scheduled visit 4 weeks after the first dose escalation.
Time frame: Week 17 Day 1 (Pre-dose, 1h post dose, 3h post dose, 5h post dose, 8h post dose , 24h post dose/ Pre-dose of Day 2), Week 20 Day 1 (Pre-dose, 3h post dose) and after Week 28, on Day 1 (Pre-dose and 3h post dose) 4 weeks after the first dose escalation
Pharmacokinetics (PK) of Alpelisib in Group 1 and Group 2: Trough Concentration (Ctrough)
The trough observed concentration of alpelisib will be assessed for Group 1 and Group 2. After Week 28, blood samples will be collected only for participants who had dose escalation at next scheduled visit 4 weeks after the first dose escalation.
Time frame: Week 17 Day 1 (Pre-dose and 24 h post dose/ Pre-dose of Day 2), Week 20 Day 1 (Pre-dose) and after Week 28, on Day 1 (Pre-dose) 4 weeks after the first dose escalation
Change From Baseline in Patient-reported Pain Assessed by Brief Pain Inventory (BPI) Worst Pain Intensity Item or Wong-Baker Faces Scale (Age Appropriate) in Pediatric and Adult Populations
Change in scores from Brief Pain Inventory (BPI) items, or Wong-Baker Faces Scale (age appropriate). The BPI item that assesses worst pain intensity in the past 24 hours will be used to assess pain intensity for adult participants (≥18 years old) and pediatric participants (≥12 years old). Participants respond to the item on an 11-point numerical rating scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). For children under 12, the Wong-Baker Faces Scale will be used in place of the BPI worst pain intensity item. This scale is a single-item that includes drawings of 6 faces that are associated with both a numeric rating and a descriptor (ranging from 0/no hurt - 10/hurts worst)
Time frame: From Baseline up to approximately 5 years
Changes From Baseline in Patient-reported Health-related Quality of Life Assessed by PROMIS-profile (Patient Reported Outcome Measurement Information System) in Pediatric and Adult Populations
Change in scores from the PROMIS-profile (Patient Reported Outcome Measurement Information System). The PROMIS Profiles are a group of PROMIS short forms measuring different domains of health-related quality of life (physical function, fatigue, ability to participate in social/peer relationships, pain interference, pain severity, anxiety, depression and sleep disturbance). All items include 5 response options, except for the pain intensity item, which has 11 response options.
Time frame: From Baseline up to approximately 5 years
Changes From Baseline in Patient-reported Overall Impression of Symptoms Assessed by Patient Global Impression of Symptom Severity (PGIS) in Pediatric and Adult Populations
Change in PGIS item. The PGIS is a single item to assess the participant's perception in the severity of their symptoms using a 5-point verbal rating scale, from "No symptoms" to "Very Severe".
Time frame: From Baseline up to approximately 5 years
Duration of Response (DOR) in Participants Who Received Alpelisib in Group 1 and Group 2
Duration of response (DOR) is defined as the time from first documented response until progression of PROS lesions by BIRC or death.
Time frame: From first documented response until progression of PROS lesions or death, assessed up to approximately 5 years
Time to Treatment Failure in Participants Who Received Alpelisib in Group 1 and Group 2
Time from randomization/alpelisib treatment start date until the discontinuation of study treatment due to lack of efficacy (including unsatisfactory therapeutic effect, disease progression) or safety reasons (including adverse events, death). Participants who complete the study or discontinue study treatment for other reasons (e.g. discontinuation due to Participant/Guardian decision, technical problems) will be censored at the date of last study treatment received.
Time frame: From Baseline up to approximately 5 years
Overall Clinical Response Rate as Assessed by Investigator in Participants Who Received Alpelisib in Group 1 and Group 2
Proportion of participants with overall clinical response reported as improvement, stable or worsening of clinical condition, as assessed by the investigator
Time frame: Week 16, 24, 40, 48, 72, 96 and thereafter every 48 weeks
Proportion of Participants With Response During the Extension Period in Group 1 and Group 2
Response (yes/no) at scheduled protocol visit. Response is defined by achieving at least 20% reduction from baseline in the sum of target lesion volumes (1 to 3 lesions, assessed by MRI by a blinded independent review committee (BIRC)), provided that none of the individual target lesions has ≥ 20% increase from baseline and in absence of progression of non-target lesions and without new lesions.
Time frame: Week 40, 48, 72, 96, 144, 192, 240 and 264.
Changes in Symptoms and Complications/Comorbidities up to Week 16 on Treatment With Alpelisib as Compared to Placebo in Group 1 and Group 2
Change in PROS-related symptoms and complications/comorbidities associated with PROS up to Week 16 among participants with symptoms and complications/comorbidities present at baseline
Time frame: Baseline up to Week 16
Changes in Symptoms and Complications/Comorbidities Associated With PROS Over Time in Group 1 and Group 2
Change in PROS-related symptoms and complications/comorbidities among participants with symptoms and complications/comorbidities present at baseline
Time frame: Baseline up to approximately 5 years
Proportion of Participants With Healthcare Visit/Hospitalized Due to PROS in Group 1 and Group 2
Proportion of participants with healthcare visit/hospitalized due to PROS will be assessed for Group 1 and Group 2.
Time frame: From Baseline up to approximately 5 years
Proportion of Participants Requiring Rescue Surgery Due to PROS in Group 1 and Group 2
Proportion of participants requiring rescue surgery due to PROS will be assessed for Group 1 and Group 2.
Time frame: From Baseline up to approximately 5 years
The study is conducted globally across 12 countries. Recruitment in Group 3 will be open after protocol amendment 5 approval in 2025.
| Milestone | Group 1 (Greater or Equal to 18 Years) - Alpelisib Arm | Group 1 (Greater or Equal to 18 Years) - Placebo Arm | Group 2 (6-17 Years) - Alpelisib Arm | Group 2 (6-17 Years) - Placebo Arm | Exploratory Group 4 (2-5 Years) All Pediatrics - Alpelisib FCT | Exploratory Group 5 (6-17 Years) All Pediatrics - Alpelisib FCT |
|---|---|---|---|---|---|---|
| Started | 54 | 27 | 56 | 28 | 7 | 16 |
| Completed core | 52 | 26 | 55 | 26 | 7 | 13 |
| Completed extension 1 | 46 | 24 | 55 | 26 | 7 | 4 |
| Full analysis set (fas) | 54 | 27 | 56 | 28 | 7 | 16 |
| Full analysis set (fas) - byl719 | 54 | 0 | 56 | 0 | 0 | 0 |
| Safety set | 54 | 27 | 56 | 28 | 7 | 16 |
| Pharmacokinetic analysis set (pas) | 51 | 25 | 56 | 26 | 7 | 16 |
| Completed | 42 | 23 | 53 | 25 | 7 | 15 |
| Not completed | 12 | 4 | 3 | 3 | 0 | 1 |
| Withdrew: Subject decision | 6 | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 1 | 1 | 1 | 0 | 1 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Unsatisfactory therapeutic effect | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Guardian decision | 0 | 0 | 0 | 1 | 0 | 0 |
A responder is defined by achieving a \>=20% reduction from baseline in the sum of target lesion volumes (via BIRC), provided that none of the individual target lesions have a \>=20% increase from baseline and in absence of progression of non target lesions and without new lesions. Confirmation of response requires a subsequent imaging assessment performed at least 4 weeks after the onset of response. Participants who permanently discontinued alpelisib prior to confirmation of response, and participants who received surgery as rescue therapy prior to confirmation of response are considered as non-responders.
| % of confirmed responder by BIRC | Group 1 (Greater or Equal to 18 Years) - Alpelisib Arm | Group 2 (6-17 Years) - Alpelisib Arm |
|---|---|---|
| Proportion of Participants Randomized to Alpelisib With a Confirmed Objective Response by BIRC in Group 1 and Group 2 | 16.7 (7.0 to 31.1) | 23.2 (11.9 to 38.3) |
A responder is defined by achieving a \>=20% reduction from baseline in the sum of target lesion volumes (via BIRC) at Week 16, provided that none of the individual target lesions have a \>=20% increase from baseline and in absence of progression of non-target lesions and without new lesions. Participants who permanently discontinued alpelisib prior to Week 16, participants who received surgery as rescue therapy prior to Week 16, and participants who had a missing/non-evaluable radiological assessment at Week 16 are considered as non-responders.
| % of responder by BIRC | Group 1 (Greater or Equal to 18 Years) - Alpelisib Arm | Group 1 (Greater or Equal to 18 Years) - Placebo Arm | Group 2 (6-17 Years) - Alpelisib Arm | Group 2 (6-17 Years) - Placebo Arm |
|---|---|---|---|---|
| Key Secondary Objective: Proportion of Participants With Response at Week 16 by BIRC in Group 1 and Group 2 | 11.1 (4.2 to 22.6) | 0 (0.0 to 12.8) | 8.9 (3.0 to 19.6) | 0 (0.0 to 12.3) |
A responder is defined by achieving a \>=20% reduction from baseline in the sum of target lesion volumes (via BIRC) at Week 24, provided that none of the individual target lesions have a \>=20% increase from baseline and in absence of progression of non-target lesions and without new lesions.
| % of confirmed responder by BIRC | Group 1 (Greater or Equal to 18 Years) - Alpelisib Arm | Group 2 (6-17 Years) - Alpelisib Arm |
|---|---|---|
| Proportion of Participants With a Response at Week 24 (by BIRC) in Groups 1 and 2 | 16.7 (7 to 31.1) | 19.6 (9.2 to 34.3) |
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a participant or clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. This includes events reported by the participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative). Treatment emergent Adverse Event (TEAEs) in this study are events that started after the first dose of study treatment and until 30 days after the last dose of study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 30 days after the last study treatment.
| Participants | Group 1 (Greater or Equal to 18 Years) - Alpelisib Arm | Group 1 (Greater or Equal to 18 Years) - Placebo Arm | Group 2 (6-17 Years) - Alpelisib Arm | Group 2 (6-17 Years) - Placebo Arm |
|---|---|---|---|---|
| Adverse Events (AEs) | 50 | 26 | 50 | 24 |
| Treatment-related AEs | 31 | 12 | 19 | 9 |
| AEs with grade >=3 | 11 | 5 | 7 | 2 |
| Treatment-related AEs with grade >=3 | 5 | 1 | 3 | 0 |
| Serious Adverse Events (SAEs) | 5 | 2 | 3 | 2 |
| Treatment-related SAEs | 3 | 0 | 1 | 0 |
| AEs leading to discontinuation | 1 | 0 | 0 | 0 |
| Treatment-related AEs leading to discontinuation | 1 | 0 | 0 | 0 |
| AEs leading to dose adjustment/interruption | 6 | 6 | 4 | 4 |
| AEs leading to dose reduction | 0 | 0 | 0 | 0 |
| AEs leading to dose interruption | 6 | 6 | 4 | 4 |
| AEs requiring additional therapy | 37 | 19 | 43 | 15 |
Type, frequency, seriousness, and severity of treatment-emergent adverse events per CTCAE v4.03 criteria in participants with PROS over time.
Results for this outcome have not been posted.
For adult and pediatric patients 12 years of age and older, the BPI item that assesses worst pain intensity in the past 24 hours was used. Patients respond to the item on an 11-point response scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). Worst pain intensity was averaged weekly over a 7-day period if a patient had completed the questionnaire for at least 4 days in the 7-day period. The weekly mean was calculated based on the available assessments. Clinically important change at Week 16 was defined as a 2-point reduction for patients who had a pain intensity score ≥ 4 at baseline. For patients with a baseline score \< 4, a 1-point reduction from baseline was also considered as a clinically important change.
| Score on a scale | Group 1 (Greater or Equal to 18 Years) - Alpelisib Arm | Group 1 (Greater or Equal to 18 Years) - Placebo Arm | Group 2 (6-17 Years) - Alpelisib Arm | Group 2 (6-17 Years) - Placebo Arm |
|---|---|---|---|---|
| Change from BL at Week 4 | -0.9 ± 1.87 | -0.2 ± 1.54 | 0.2 ± 0.73 | 0.3 ± 0.82 |
| Change from BL at Week 8 | -1.2 ± 2.13 | -0.7 ± 1.43 | -0.3 ± 0.91 | 0.1 ± 0.69 |
| Change from BL at Week 12 | -0.9 ± 2.55 | -0.8 ± 1.41 | -0.4 ± 1.01 | 0.4 ± 0.62 |
| Change from BL at Week 16 | -1.3 ± 2.46 | -0.1 ± 1.49 | -0.4 ± 1.34 | 0.3 ± 1.14 |
A Patient Global Impression of Symptom Severity item was used to understand the overall severity of symptoms experienced and clinical meaningfulness of treatment effects experienced during this study. This item included 5 response options: no symptoms, mild, moderate, severe, and very severe.
| Participants | Group 1 (Greater or Equal to 18 Years) - Alpelisib Arm | Group 1 (Greater or Equal to 18 Years) - Placebo Arm | Group 2 (6-17 Years) - Alpelisib Arm | Group 2 (6-17 Years) - Placebo Arm |
|---|---|---|---|---|
| Week 4 — No symptoms | 12 | 9 | 15 | 3 |
| Week 4 — Mild | 20 | 5 | 6 | 3 |
| Week 4 — Moderate | 14 | 10 | 4 | 2 |
| Week 4 — Severe | 6 | 2 | 0 | 0 |
| Week 4 — Very severe | 1 | 0 | 0 | 0 |
| Week 8 — No symptoms | 12 | 7 | 17 | 3 |
| Week 8 — Mild | 20 | 6 | 6 | 2 |
| Week 8 — Moderate | 11 | 10 | 4 | 3 |
| Week 8 — Severe | 7 | 1 | 1 | 0 |
| Week 8 — Very severe | 0 | 2 | 0 | 0 |
| Week 16 — No symptoms | 15 | 8 | 18 | 2 |
| Week 16 — Mild | 14 | 6 | 6 | 4 |
| Week 16 — Moderate | 15 | 7 | 2 | 1 |
| Week 16 — Severe | 6 | 5 | 0 | 0 |
| Week 16 — Very severe | 1 | 0 | 0 | 0 |
Percentage change from baseline in the sum of target lesion volume, MRI-measurable non-target lesion volume and all MRI measurable (target an non-target) lesion volume as assessed by BIRC. Target lesions are defined as anatomically reproducibly defined tissue(s) masses, which may be composed of one or several tissue types, and can be accurately measured by imaging technique MRI. Target lesion(s) (up to 3) should be identified at screening, be at least 2 cm in the longest diameter at baseline (for each selected lesion) and may be further reproducibly assessed by MRI. MRI-measurable non-target lesions are defined as all anatomic lesions other than selected as target and may be measured at radiologic assessment (at least 2 cm in the longest diameter at baseline, the volume may be further reproducibly assessed by MRI).
Results for this outcome have not been posted.
Percentage change from baseline in other non-target lesions (by BIRC). Non Target lesions are defined as: * Anatomic lesions, limb/trunkal areas affected by PROS, organomegaly when they may be measured only by caliper/ruler (e.g., circumference of changed limb or body part) * Truly non-measurable lesions (e.g., small lesions less than 2 cm on MRI, superficial visual lesions, masses, organomegaly, PROS-related enlargement of anatomic area identified by physical exam that is not measurable by reproducible imaging technique)
Results for this outcome have not been posted.
The proportion of patients with new lesions (as assessed by BIRC) will be assessed throughout the study.
Results for this outcome have not been posted.
Maximum concentration of alpelisib following drug administration will be assessed for Group 1 and Group 2. After Week 28, blood samples will be collected only for participants who had dose escalation at next scheduled visit 4 weeks after the first dose escalation.
Results for this outcome have not been posted.
The trough observed concentration of alpelisib will be assessed for Group 1 and Group 2. After Week 28, blood samples will be collected only for participants who had dose escalation at next scheduled visit 4 weeks after the first dose escalation.
Results for this outcome have not been posted.
Change in scores from Brief Pain Inventory (BPI) items, or Wong-Baker Faces Scale (age appropriate). The BPI item that assesses worst pain intensity in the past 24 hours will be used to assess pain intensity for adult participants (≥18 years old) and pediatric participants (≥12 years old). Participants respond to the item on an 11-point numerical rating scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). For children under 12, the Wong-Baker Faces Scale will be used in place of the BPI worst pain intensity item. This scale is a single-item that includes drawings of 6 faces that are associated with both a numeric rating and a descriptor (ranging from 0/no hurt - 10/hurts worst)
Results for this outcome have not been posted.
Change in scores from the PROMIS-profile (Patient Reported Outcome Measurement Information System). The PROMIS Profiles are a group of PROMIS short forms measuring different domains of health-related quality of life (physical function, fatigue, ability to participate in social/peer relationships, pain interference, pain severity, anxiety, depression and sleep disturbance). All items include 5 response options, except for the pain intensity item, which has 11 response options.
Results for this outcome have not been posted.
Change in PGIS item. The PGIS is a single item to assess the participant's perception in the severity of their symptoms using a 5-point verbal rating scale, from "No symptoms" to "Very Severe".
Results for this outcome have not been posted.
Duration of response (DOR) is defined as the time from first documented response until progression of PROS lesions by BIRC or death.
Results for this outcome have not been posted.
Time from randomization/alpelisib treatment start date until the discontinuation of study treatment due to lack of efficacy (including unsatisfactory therapeutic effect, disease progression) or safety reasons (including adverse events, death). Participants who complete the study or discontinue study treatment for other reasons (e.g. discontinuation due to Participant/Guardian decision, technical problems) will be censored at the date of last study treatment received.
Results for this outcome have not been posted.
Proportion of participants with overall clinical response reported as improvement, stable or worsening of clinical condition, as assessed by the investigator
Results for this outcome have not been posted.
Response (yes/no) at scheduled protocol visit. Response is defined by achieving at least 20% reduction from baseline in the sum of target lesion volumes (1 to 3 lesions, assessed by MRI by a blinded independent review committee (BIRC)), provided that none of the individual target lesions has ≥ 20% increase from baseline and in absence of progression of non-target lesions and without new lesions.
Results for this outcome have not been posted.
Change in PROS-related symptoms and complications/comorbidities associated with PROS up to Week 16 among participants with symptoms and complications/comorbidities present at baseline
Results for this outcome have not been posted.
Change in PROS-related symptoms and complications/comorbidities among participants with symptoms and complications/comorbidities present at baseline
Results for this outcome have not been posted.
Proportion of participants with healthcare visit/hospitalized due to PROS will be assessed for Group 1 and Group 2.
Results for this outcome have not been posted.
Proportion of participants requiring rescue surgery due to PROS will be assessed for Group 1 and Group 2.
Results for this outcome have not been posted.
Collected over From first dose of study treatment up to the cut-off date for the interim analysis (20-Mar-2024), approximately 35 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 (Greater or Equal to 18 Years) - Alpelisib Arm | 0/54 (0%) | 5/54 (9.3%) | 47/54 (87%) |
| Group 1 (Greater or Equal to 18 Years) - Placebo Arm | 0/27 (0%) | 2/27 (7.4%) | 24/27 (88.9%) |
| Group 1 (Greater or Equal to 18 Years) Alpelisib Period/Alpelisib Arm | 0/54 (0%) | 16/54 (29.6%) | 52/54 (96.3%) |
| Group 1 (Greater or Equal to 18 Years) Alpelisib Period/Placebo Arm | 0/26 (0%) | 3/26 (11.5%) | 26/26 (100%) |
| Group 1 (Greater or Equal to 18 Years) All Adults in Alpelisib Period | 0/80 (0%) | 19/80 (23.8%) | 78/80 (97.5%) |
| Group 2 (6-17 Years) - Alpelisib Arm | 0/56 (0%) | 3/56 (5.4%) | 45/56 (80.4%) |
| Group 2 (6-17 Years) - Placebo Arm | 1/28 (3.6%) | 2/28 (7.1%) | 21/28 (75%) |
| Group 2 (6-17 Years) Alpelisib Period Alpelisib Arm | 0/56 (0%) | 8/56 (14.3%) | 53/56 (94.6%) |
| Group 2 (6-17 Years) Alpelisib Period Placebo Arm | 0/26 (0%) | 2/26 (7.7%) | 23/26 (88.5%) |
| Group 2 (6-17 Years) All Pediatrics in Alpelisib Period | 0/82 (0%) | 10/82 (12.2%) | 76/82 (92.7%) |
| Group 4 (2-5 Years) All Pediatrics | 0/7 (0%) | 3/7 (42.9%) | 7/7 (100%) |
| Group 5 (6-17 Years) All Pediatrics | 0/16 (0%) | 2/16 (12.5%) | 14/16 (87.5%) |
| Event | Group 1 (Greater or Equal to 18 Years) - Alpelisib Arm | Group 1 (Greater or Equal to 18 Years) - Placebo Arm | Group 1 (Greater or Equal to 18 Years) Alpelisib Period/Alpelisib Arm | Group 1 (Greater or Equal to 18 Years) Alpelisib Period/Placebo Arm | Group 1 (Greater or Equal to 18 Years) All Adults in Alpelisib Period | Group 2 (6-17 Years) - Alpelisib Arm | Group 2 (6-17 Years) - Placebo Arm | Group 2 (6-17 Years) Alpelisib Period Alpelisib Arm | Group 2 (6-17 Years) Alpelisib Period Placebo Arm | Group 2 (6-17 Years) All Pediatrics in Alpelisib Period | Group 4 (2-5 Years) All Pediatrics | Group 5 (6-17 Years) All Pediatrics |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/54 | 0/27 | 2/54 | 0/26 | 2/80 | 0/56 | 0/28 | 0/56 | 0/26 | 0/82 | 2/7 | 1/16 |
| IntussusceptionGastrointestinal disorders | 0/54 | 0/27 | 0/54 | 0/26 | 0/80 | 0/56 | 0/28 | 0/56 | 0/26 | 0/82 | 1/7 | 0/16 |
| Staphylococcal infectionInfections and infestations | 0/54 | 0/27 | 0/54 | 0/26 | 0/80 | 0/56 | 0/28 | 0/56 | 0/26 | 0/82 | 0/7 | 1/16 |
| CellulitisInfections and infestations | 1/54 | 1/27 | 1/54 | 1/26 | 2/80 | 0/56 | 0/28 | 1/56 | 1/26 | 2/82 | 0/7 | 0/16 |
| ErysipelasInfections and infestations | 0/54 | 1/27 | 2/54 | 1/26 | 3/80 | 0/56 | 0/28 | 0/56 | 0/26 | 0/82 | 0/7 | 0/16 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/54 | 0/27 | 0/54 | 1/26 | 1/80 | 0/56 | 0/28 | 0/56 | 0/26 | 0/82 | 0/7 | 0/16 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/54 | 0/27 | 0/54 | 0/26 | 0/80 | 0/56 | 0/28 | 0/56 | 1/26 | 1/82 | 0/7 | 0/16 |
| Suicide attemptPsychiatric disorders | 0/54 | 0/27 | 0/54 | 1/26 | 1/80 | 0/56 | 0/28 | 0/56 | 0/26 | 0/82 | 0/7 | 0/16 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/54 | 0/27 | 0/54 | 1/26 | 1/80 | 0/56 | 0/28 | 0/56 | 0/26 | 0/82 | 0/7 | 0/16 |
| Abdominal painGastrointestinal disorders | 1/54 | 0/27 | 2/54 | 0/26 | 2/80 | 0/56 | 0/28 | 0/56 | 0/26 | 0/82 | 0/7 | 0/16 |
| Event | Group 1 (Greater or Equal to 18 Years) - Alpelisib Arm | Group 1 (Greater or Equal to 18 Years) - Placebo Arm | Group 1 (Greater or Equal to 18 Years) Alpelisib Period/Alpelisib Arm | Group 1 (Greater or Equal to 18 Years) Alpelisib Period/Placebo Arm | Group 1 (Greater or Equal to 18 Years) All Adults in Alpelisib Period | Group 2 (6-17 Years) - Alpelisib Arm | Group 2 (6-17 Years) - Placebo Arm | Group 2 (6-17 Years) Alpelisib Period Alpelisib Arm | Group 2 (6-17 Years) Alpelisib Period Placebo Arm | Group 2 (6-17 Years) All Pediatrics in Alpelisib Period | Group 4 (2-5 Years) All Pediatrics | Group 5 (6-17 Years) All Pediatrics |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 2/54 | 0/27 | 4/54 | 2/26 | 6/80 | 6/56 | 2/28 | 10/56 | 7/26 | 17/82 | 4/7 | 5/16 |
| PyrexiaGeneral disorders | 5/54 | 0/27 | 8/54 | 2/26 | 10/80 | 5/56 | 1/28 | 17/56 | 8/26 | 25/82 | 4/7 | 5/16 |
| DiarrhoeaGastrointestinal disorders | 16/54 | 5/27 | 21/54 | 8/26 | 29/80 | 5/56 | 3/28 | 15/56 | 6/26 | 21/82 | 2/7 | 8/16 |
| AlopeciaSkin and subcutaneous tissue disorders | 11/54 | 1/27 | 21/54 | 4/26 | 25/80 | 1/56 | 0/28 | 6/56 | 2/26 | 8/82 | 1/7 | 3/16 |
| HeadacheNervous system disorders | 10/54 | 4/27 | 16/54 | 6/26 | 22/80 | 11/56 | 3/28 | 20/56 | 5/26 | 25/82 | 2/7 | 2/16 |
| COVID-19Infections and infestations | 6/54 | 4/27 | 17/54 | 3/26 | 20/80 | 9/56 | 3/28 | 13/56 | 2/26 | 15/82 | 0/7 | 1/16 |
| Decreased appetiteMetabolism and nutrition disorders | 6/54 | 1/27 | 6/54 | 4/26 | 10/80 | 4/56 | 1/28 | 6/56 | 1/26 | 7/82 | 2/7 | 2/16 |
| Abdominal painGastrointestinal disorders | 9/54 | 1/27 | 13/54 | 3/26 | 16/80 | 5/56 | 2/28 | 14/56 | 7/26 | 21/82 | 0/7 | 1/16 |
| NasopharyngitisInfections and infestations | 5/54 | 1/27 | 12/54 | 1/26 | 13/80 | 4/56 | 4/28 | 9/56 | 7/26 | 16/82 | 1/7 | 2/16 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/54 | 1/27 | 10/54 | 3/26 | 13/80 | 2/56 | 1/28 | 13/56 | 4/26 | 17/82 | 0/7 | 0/16 |
| Age, Customized(Participants) | Group 1 (Greater or Equal to 18 Years) - Alpelisib Arm | Group 1 (Greater or Equal to 18 Years) - Placebo Arm | Group 2 (6-17 Years) - Alpelisib Arm | Group 2 (6-17 Years) - Placebo Arm | Exploratory Group 4 (2-5 Years) All Pediatrics - Alpelisib FCT | Exploratory Group 5 (6-17 Years) All Pediatrics - Alpelisib FCT | Total |
|---|---|---|---|---|---|---|---|
| Children, 2 - < 6 years | 0 | 0 | 0 | 0 | 7 | 0 | 7 |
| Children, 6 - < 12 years | 0 | 0 | 28 | 19 | 0 | 12 | 59 |
| Adolescent, 12 - < 18 years | 0 | 0 | 28 | 9 | 0 | 4 | 41 |
| 18 - < 65 years | 54 | 27 | 0 | 0 | 0 | 0 | 81 |
| Sex: Female, Male(Participants) | Group 1 (Greater or Equal to 18 Years) - Alpelisib Arm | Group 1 (Greater or Equal to 18 Years) - Placebo Arm | Group 2 (6-17 Years) - Alpelisib Arm | Group 2 (6-17 Years) - Placebo Arm | Exploratory Group 4 (2-5 Years) All Pediatrics - Alpelisib FCT | Exploratory Group 5 (6-17 Years) All Pediatrics - Alpelisib FCT | Total |
|---|---|---|---|---|---|---|---|
| Female | 34 | 14 | 27 | 12 | 3 | 8 | 98 |
| Male | 20 | 13 | 29 | 16 | 4 | 8 | 90 |
| Race (NIH/OMB)(Participants) | Group 1 (Greater or Equal to 18 Years) - Alpelisib Arm | Group 1 (Greater or Equal to 18 Years) - Placebo Arm | Group 2 (6-17 Years) - Alpelisib Arm | Group 2 (6-17 Years) - Placebo Arm | Exploratory Group 4 (2-5 Years) All Pediatrics - Alpelisib FCT | Exploratory Group 5 (6-17 Years) All Pediatrics - Alpelisib FCT | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 6 | 3 | 10 | 3 | 0 | 2 | 24 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| White | 48 | 22 | 42 | 25 | 7 | 13 | 157 |
| More than one race | 0 | 1 | 2 | 0 | 0 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Apr 2021 to primary completion in Mar 2024, 35 months.
Results were first posted in Feb 2025, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpelisib